Skip to content

Study · In vitro (cells) · 2020

2 results

SUN-101 Support for a New Therapeutic Approach of Using a Low-Dose FGFR Tyrosine Kinase Inhibitor (Infigratinib) for Achondroplasia

Demuynck B, Filipo J, Li G, Dambkowski C, Legeai-Mallet L

Journal of the Endocrine Society8 May 2020

PMCIDPMC7209571 (opens in a new tab)PepBankPUB-90896682
Read at sourceSource pageAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. No result from this study comes from people.

  1. 01LabIn vitro (cells)Activity measurement

    In TAN 4-18 chondrocytes, vosoritide at 10-4M significantly improved the MAPK-related response versus FGF18-treated chondrocytes (p<0.05).

    In plain wordsIn cells, vosoritide at 10-4M significantly improved the measured response compared with FGF18-treated chondrocytes.

    Peptide
    Vosoritide
    Outcome
    Direction not reportedMAPK response at 10-4M
    Study

    humann: not reported in source

    FGF18-treated TAN 4-18 chondrocytes
    Comparator
    FGF18-treated chondrocytes
    Outcome group
    Receptor activity and mechanism · Pharmacology
    Studied dose
    10-4MAs given in this study (human).

    Source sentences

    Summary
    With vosoritide treatment, a concentration of 10-4M led to statistically significant improvements compared with FGF18-treated chondrocytes (p<0.05), although this was not seen at 10-5M.
    1 context sentence
    Summary · context
    TAN 4-18-chondrocytes, a human chondrocyte line expressing a heterozygous Y373C FGFR3 mutation, were treated with multiple concentrations of infigratinib and vosoritide and MAPK levels were measured.
  2. 02LabIn vitro (cells)Activity measurement

    In TAN 4-18 chondrocytes, vosoritide at 10-5M did not show significant improvement compared with FGF18-treated chondrocytes.

    In plain wordsIn cells, vosoritide at 10-5M did not show significant improvement compared with FGF18-treated chondrocytes.

    Peptide
    Vosoritide
    Outcome
    No significant changeMAPK response at 10-5M
    Study

    humann: not reported in source

    FGF18-treated TAN 4-18 chondrocytes
    Comparator
    FGF18-treated chondrocytes
    Outcome group
    Receptor activity and mechanism · Pharmacology
    Studied dose
    10-5MAs given in this study (human).

    Source sentences

    Summary
    With vosoritide treatment, a concentration of 10-4M led to statistically significant improvements compared with FGF18-treated chondrocytes (p<0.05), although this was not seen at 10-5M.
    1 context sentence
    Summary · context
    TAN 4-18-chondrocytes, a human chondrocyte line expressing a heterozygous Y373C FGFR3 mutation, were treated with multiple concentrations of infigratinib and vosoritide and MAPK levels were measured.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:37 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.